Tangeretin attenuates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via the PI3K/Akt pathway

Background: Pulmonary fibrosis (PF) is a terminal pathological change in a variety of lung diseases characterized by excessive deposition of extracellular matrix, for which effective treatment is lacking. Tangeretin (Tan), a flavonoid derived from citrus, has been shown to have a wide range of pharm...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiang Li (Author), Qian Wei (Author), Ke Song (Author), Youxin Wang (Author), Yuxin Yang (Author), Miao Li (Author), Jiaying Yu (Author), Guangxu Su (Author), Luyuan Peng (Author), Bendong Fu (Author), Pengfei Yi (Author)
Format: Book
Published: Frontiers Media S.A., 2023-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_aff2bb6173f34d03b55ebe1ad8e15f6c
042 |a dc 
100 1 0 |a Jiang Li  |e author 
700 1 0 |a Qian Wei  |e author 
700 1 0 |a Ke Song  |e author 
700 1 0 |a Youxin Wang  |e author 
700 1 0 |a Yuxin Yang  |e author 
700 1 0 |a Miao Li  |e author 
700 1 0 |a Jiaying Yu  |e author 
700 1 0 |a Guangxu Su  |e author 
700 1 0 |a Luyuan Peng  |e author 
700 1 0 |a Bendong Fu  |e author 
700 1 0 |a Pengfei Yi  |e author 
245 0 0 |a Tangeretin attenuates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via the PI3K/Akt pathway 
260 |b Frontiers Media S.A.,   |c 2023-09-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2023.1247800 
520 |a Background: Pulmonary fibrosis (PF) is a terminal pathological change in a variety of lung diseases characterized by excessive deposition of extracellular matrix, for which effective treatment is lacking. Tangeretin (Tan), a flavonoid derived from citrus, has been shown to have a wide range of pharmacological effects. This study aimed to investigate the role and potential mechanisms of Tan on pulmonary fibrosis.Methods: A model of pulmonary fibrosis was established by administering bleomycin through tracheal drip, followed by administering Tan or pirfenidone through gavage. HE and Masson staining were employed to assess the extent of pulmonary fibrosis. Subsequently, Western blot, enzyme-linked immunosorbent assay (ELISA), RNA sequencing, and immunohistochemistry techniques were employed to uncover the protective mechanism of Tan in PF mice. Furthermore, A549 cells were stimulated with TGF-β1 to induce epithelial-mesenchymal transition (EMT) and demonstrate the effectiveness of Tan in mitigating PF.Results: Tan significantly ameliorated bleomycin-induced pulmonary fibrosis, improved fibrotic pathological changes, and collagen deposition in the lungs, and reduced lung inflammation and oxidative stress. The KEGG pathway enrichment analysis revealed a higher number of enriched genes in the PI3K/Akt pathway. Additionally, Tan can inhibit the EMT process related to pulmonary fibrosis.Conclusion: Taken together, the above research results indicate that Tan suppresses inflammation, oxidative stress, and EMT in BLM-induced pulmonary fibrosis via the PI3K/Akt pathway and is a potential agent for the treatment of pulmonary fibrosis. 
546 |a EN 
690 |a pulmonary fibrosis 
690 |a tangeretin 
690 |a PI3K/Akt signaling pathway 
690 |a epithelial-mesenchymal transition 
690 |a bleomycin 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 14 (2023) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2023.1247800/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/aff2bb6173f34d03b55ebe1ad8e15f6c  |z Connect to this object online.